A2461912
CUDC-101 , ≥98% , 1012054-59-9
Synonym(s):
7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide;Heptanamide, 7-[[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-hydroxy
CAS NO.:1012054-59-9
Empirical Formula: C24H26N4O4
Molecular Weight: 434.49
MDL number: MFCD15528940
Pack Size | Price | Stock | Quantity |
10MG | RMB415.20 | In Stock |
|
25mg | RMB959.20 | In Stock |
|
50MG | RMB1919.20 | In Stock |
|
100MG | RMB3039.20 | In Stock |
|
250mg | RMB5599.20 | In Stock |
|
others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
Melting point: | 174-177℃ |
Density | 1.28 |
storage temp. | -20°C |
solubility | DMSO: soluble |
pka | 9.47±0.20(Predicted) |
form | solid |
color | White or off-white |
Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
InChIKey | PLIVFNIUGLLCEK-UHFFFAOYSA-N |
Description and Uses
CUDC-101 (1012054-59-9) is a novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2,? IC50?= 4.4, 2.4 and 15.7 nM respectively.1?It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors.1,2
Inhibitor of HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, respectively.
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H315-H319-H335 |
Precautionary statements | P280-P305+P351+P338 |
WGK Germany | 3 |